Delivery Order SPE2DR25D2009-SPE2DR26FJ3E4
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $16,968.48 for Dapagliflozin 10 mg tablets (30-count packaging) on November 14, 2025, with an ultimate completion date of November 17, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a specific pharmaceutical fulfillment under DLA's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a contract ceiling value of $1,949.87. This firm fixed-price delivery order, with an ultimate completion date of October 28, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $2,975.85 and an ultimate completion date of October 31, 2025. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dapagliflozin is a...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Dapagliflozin 10 mg tablets (30-count units) valued at $30,163.79 under a firm fixed-price contract awarded September 19, 2025. This competitively awarded, non-set-aside delivery order is scheduled for completion by September 22, 2025, with performance taking place at AmerisourceBergen's Conshohocken, Pennsylvania headquarters. The award represents a continuation of the company's critical role as a...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $5,492.03 and an ultimate completion date of September 8, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dapagliflozin is a diabetes...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dapagliflozin 10 mg tablets in a quantity of 30 units, valued at $2,024.45. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract carries no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 5 mg tablets in quantities of 30 units, with a contract ceiling value of $1,761.68. This competitively awarded, non-set-aside delivery order carries a firm fixed price structure and is scheduled for completion by October 30, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 5 mg tablets in quantities of 30 units. This firm fixed-price delivery order, issued on September 29, 2025, carries a ceiling value of $14,223.60 and is scheduled for completion by September 30, 2025. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Dapagliflozin 5 mg tablets in quantities of 30 units, with a ceiling value of $8,774.89. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by August 20, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,357.78 for 30-tablet units of Dapagliflozin 5 mg, a diabetes medication. This non-set-aside, competitively awarded contract was executed on November 6, 2025, with an ultimate completion date of November 7, 2025. The firm fixed price delivery order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- SPE2DR25D2009Indefinite Delivery Contract
- SPE2DR25D2009-SPE2DR26FJ3E4Delivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $3,149.25 for Dapagliflozin 5 mg tablets (30-count packaging) on November 14, 2025, with an ultimate completion date of November 17, 2025. This competitively awarded, firm fixed-price delivery order was issued under a non-set-aside procurement. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical supply vehicle supporting military healthcare programs and federal medical procurement needs. AmerisourceBergen's federal contract portfolio with DLA demonstrates its substantial capability to supply a wide range of pharmaceutical products, including diabetes medications, specialty therapeutics, and medical supplies to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Dapagliflozin, an SGLT2 inhibitor used in diabetes and heart failure management, reflects the company's role as a critical vendor for federal military and veteran healthcare systems' pharmaceutical needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 11/14/25 |